Abstract
Background
Gastric cancer is one of the most aggressive malignancies, with an extremely poor prognosis, and is the second leading cause of cancer death worldwide [1] . The prevalence of gastric cancer in China is amongst the highest in the world, along with Japan and Korea. Lowest rates are associated with the more developed regions such as Northern Europe and North America. By the time the patient is clinically diagnosed, the gastric cancer has often grown beyond the limits of curative resection. This reality has raised therapeutic problems, and new early diagnostic tools and therapeutic techniques concerning this disease are urgently needed. CD133 is a pentaspan transmembrane glycoprotein, with a molecular weight of 120 kDa [2] . Although it was initially considered to be one marker of hematopoietic stem cells, CD133 mRNA transcript could also be found in normal non-lymphoid hematopoietic tissue [2] . CD133 is overexpressed in various solid tumours [3] [4] [5] [6] [7] , including colon cancer and glioblastoma [8, 9] . O'Brien et al. [9] performed purification of CD133-positive cells in colon carcinoma by flow cytometry and transplanted them into mice, leading to the formation of tumours in renal subcapsule, suggesting that CD133 may be a cancer stem cell marker for colon carcinoma. Recently, Smith and colleagues have shown that a moderate to high percentage of gastric cancer tumor samples have CD133 expression with moderate to strong membranous and apical expression. No significant association with tumor stage or grade was identified but this conclusion was based on a limited number of cases studied.
They identified CD133 as a potential therapeutic target for antibody-drug conjugates in gastric cancer [10] , raising the possibility of molecular targeting therapy in this most aggressive malignancy. CD133 expression as a prognostic marker has been found in colorectal cancer [11] [12] [13] [14] [15] [16] [17] [18] and brain tumours [19] [20] [21] but it is still unclear if CD133 can be used as a prognostic marker in pancreatic cancer [22] , ovarian cancer [23] , hepatocellular cancer [24, 25] and non-small cell lung carcinoma [26] . Whether CD133 is a prognostic marker in gastric cancer is still unclear since to date no extensive study has been performed correlating CD133 expression with clinicopathological features and prognosis. Ki-67 is a well-recognized nuclear antigen-specific marker associated with cellular proliferation, and primarily used to judge the activity of proliferation. The relationship between CD133 and Ki-67 in gastric cancer has not yet been investigated. We performed an immunohistochemical study to investigate the possible role of the expression of CD133 in clinicopathology and prognosis, as well as the relationship between CD133 and Ki-67 in 336 cases of gastric adenocarcinoma. It is hoped that the study will give information on the pathogenesis of this disease.
Methods

Biopsy Specimens
Paraffin embedded sections of 336 gastric adenocarcinomas with 58 adjacent dysplastic mucosas and 60 distal normal gastric tissues were obtained from the Department of Pathology, Chinese People's Liberation Army (PLA) General Hospital (Beijing, China). Ethical approval for this study was not required by our institution as the experiments carried out did not relate to patient's privacy, impairment or treatment. The age of the patients ranged from 18-85 years, with an average of 58.1 years. Two hundred seventy-four were men and 62 were women. Seventeen were at grade 1, 65 at grade 2 and 254 at grade 3, according to histological grading. Sixty-six were at stage I, 77 at stage II, 147 at stage III and 46 at stage IV, according to clinical staging of TNM, respectively. Lymphatic metastasis in regional nodes at operation was confirmed in 225 cancers of this study.
Immunohistochemistry
All samples were fixed in 10% buffered formalin and embedded in paraffin. Sections were cut 4 μM thick from wax blocks, mounted on to APES-coated glass slides. Slides were deparaffinized in xylene twice for 10 minutes, rehydrated through graded ethanols to distilled water before incubation for 15 minutes with 3% hydrogen peroxidase-methanol to inhibit endogenous peroxidase activity, and heated in 0.01 M citrate buffer (pH 6.0) in a microwave oven for 5 minutes at 100°C; after boiling for antigen retrieval. Then the slides were taken out of microwave oven and cooled to room temperature for 30 minutes. After incubating for 15 minutes in a blocking solution containing 10% normal goat serum in PBS, sections were incubated at 4°C overnight in a humidified chamber with rabbit polyclonal antibody to human CD133 (Abcam Inc., Cambridge, MA, USA) diluted 1:100 in blocking solution and mouse mononal antibody to human Ki-67 (Zymed Laboratories Inc., South San Francisco, CA) diluted 1:100 in blocking solution. The sections were rinsed in PBS and incubated for 20 minutes with Polyperoxidase-anti-mouse/rabbit IgG (Zymed). After washing in PBS, 3,3'-Diaminobenzidine was used as the chromogen. Slides were counterstained for 3 minutes with hematoxylin solution. Brain medulloblastoma tissue was used as a positive control, whereas the primary antibody was replaced by 0.01 M PBS as a negative control.
Evaluation of score
In scoring expression of CD133 and Ki-67 protein, both the extent and intensity of immunopositivity were considered, according to Hao et al [27] . The intensity of positivity was scored as follows: 0, negative; 1, weak; 2, moderate; 3, strong. The extent of positivity was scored according to the percentage of cells showing positive staining: 0, < 5%; 1, > 5-25%; 2, > 25-50%; 3, > 50-75%; 4, > 75% of the cells in the respective lesions. The final score was determined by multiplying the intensity of positivity and the extent of positivity scores, yielding a range from 0 to 12. The expression for CD133 and Ki-67 was considered positive when the scores were ≥5.
Statistical Analysis
Fisher's exact test (two sided), Pearson Chi's square test for trends in proportions, Spearman's correlation coefficient test, and Kaplan-Meier's method with log rank test or Cox Regression method for univariate or multivariate overall survival analysis were used to assess the associations between expression of CD133 or Ki-67 and clinicopathological indices by SPSS 15.0 for Windows (Chicago, IL). A P < 0.05 was considered statistically significant.
Results
Expression of CD133 in gastric adenocarcinoma
CD133 protein was expressed positively in 57.4% (193 out of 336) of gastric adenocarcinoma, 36.2% (21 out of 58) of adjacent dysplastic epithelia and 28.3% (17 out of 60) of distal normal mucosa. The localization of CD133 protein was primarily in the membrane and cytoplasm of cancer cells (Figure 1) . In well-differentiated adenocarcinoma, CD133 protein was found predominantly around the lumen of cancerous gland (Figure 2) . A very significant difference was found in the expression of CD133 protein between gastric adenocarcinoma and normal mucosa or adjacent dysplastic tissues (P = 0.0001; P = 0.004). There was no difference in CD133 expression between normal mucosa and adjacent dysplastic mucosa (P = 0.432).
The association between expression of CD133 and clinicopathological features
The gastric adenocarcinoma with positive expression of CD133 was 41.2% (7 out of 17) at grade 1, 46.2% (30 out of 65) at grade 2 and 61.4% (156 out of 254) at grade 3, respectively, thus the association between expression of CD133 and histological grade was statistically significant (P = 0.032) ( Table 1) . With respect to the TNM tumor staging adenocarcinoma with positive expression of CD133 was 28.8% (19 out of 66) at stage I, 49.4% (38 out of 77) at stage II, 66.7% (98 out of 147) at stage III and 82.6% (38 out of 46) at stage IV, respectively. Statistically, the positive expression of CD133 correlated with the more advanced clinical stage (P = 0.0001). Expression of CD133 was also found to positively correlate with the tumour size (P = 0.0001), invasive depth ( Figure 3 ; P = 0.0001) and metastasis in the regional lymph nodes (P = 0.0001), but not with the age of the patients (P = 0.434) ( Table 1) . Follow-up data showed that a significantly decreasing trend in 5-year survival was observed in patients with the expression of CD133 (P = 0.0001) ( Table  1 ). There was also a significant difference in the overall mean survival time between the carcinomas with expression of CD133 (36.4 months) and those without (66.0 months) (Log rank = 53.80; P = 0.0001) (Figure 4) . CD133 was an independent prognostic factor by multivariate analysis (P = 0.0001).
The association between CD133 and Ki-67
Ki-67 was positive in 58.3% (196 out of 336) cases of gastric adenocarcinoma and associated with clinicopathological features such as tumour size, invasive depth, metastasis in regional lymph nodes, histological grade, clinical stage and prognosis ( Figure 5 ; Table 1 ). The positive correlation between CD133 and Ki-67 was found (r = 0.188, P = 0.001).
Discussion
Cancer stem cells, also known as tumour initiating cells, refer to a small side population of tumour cells with unlimited self-renewal activity and potentially promote the formation of tumour, according to the cancer stem cell (CSC) hypothesis that has emerged recently [28] [29] [30] [31] [32] . There is currently heightened interest in the utility of using CD133 as a marker to identify the tumor stem cell population for a variety of malignancies [3] [4] [5] 8] Recently, CD133 was found to be highly expressed in more or equal to 50% of gastric, pancreatic and intrahepatic cholangiocarcinomas [10] . Quantitative flow cytometric analysis showed that a panel of established gastric cancer cell lines expressed CD133 at levels higher than normal epithelial cells. However, it has also been found that CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors [33, 34] . A murine anti-human CD133 antibody conjugated to a potent cytotoxic drug, monomethyl auristatin F (MMAF), effectively inhibited the growth and induced apoptosis of KATO III gastric cancer cells in vitro [10] . Therefore, anti-CD133 antibody-drug conjugates may warrant further evaluation as a molecular therapeutic strategy to eradicate CD133-positive tumour cells in gastric cancer. CD133 expression as a prognostic marker has been found in colorectal cancer [11] [12] [13] [14] [15] [16] [17] [18] and brain tumours [19] [20] [21] , although it is still controversial for ovarian cancer and non-small cell lung cancer. There are no reports on the prognostic significance of CD133 expres- sion or correlation with Ki-67 in gastric cancer. In this study the positive expression of CD133 is found in 57.4% and is closely related to the worst prognosis of gastric adenocarcinoma. Our results indicate that the expression of CD133 may be involved in tumor size, invasive depth and histological grade of gastric tumor, which are in agreement with previous reports on colorectal cancer [16, 17] . In this research, the expression of CD133 positively correlates with the shorter survival time, suggesting CD133-positive cells may contain more cancer stem-like cells. Thus residual cancer stem-like cells after routine therapy may lead to tumour recurrence and metastasis through the self-renewal and multilineage differentiation with agreement of cancer stem cell hypothesis [35, 36] . It implies that CD133 may be one of the specific molecular markers in prognosis of gastric adenocarcinoma. The results of our study, that Ki-67 expression corresponds with tumor size, degree of differentiation, depth of invasion, lymphatic metastasis, TNM staging and prognosis, are associated with a previous report [37] . This research also shows that CD133 positively correlates with Ki-67, implying higher putative proliferative activity in CD133-positive cancer cells, which corresponds with the results from Ieta, et al. [35] . Taken together, CD133 is highly expressed in the cancer cells of gastric adenocarcinoma. The combined detection of CD133 and Ki-67 expression, to some extent, can reflect the biological behavior of gastric cancer cells, thus guiding the choice of chemotherapy and molecular targeting therapy. 
